Topical Therapies for Psoriasis in Phase 3 Trials
Buechler CR, Veenstra J, and Gold LS. Topical Therapies for Psoriasis in Phase 3 Trials. Current Dermatology Reports 2020; 9(4):331-338.
Current Dermatology Reports
Purpose of Review: This review will discuss new topical therapeutics for psoriasis that have undergone or published phase III trials in the last 5 years, as well as promising therapeutics in development.
Recent Findings: New corticosteroid-only additions to the marketplace include formulations that improve absorption and ease-of-use, including betamethasone dipropionate (BD) 0.05% spray, halobetasol propionate (HP) 0.05% foam and 0.01% lotion, and clobetasol propionate 0.025% cream. Combination therapies include BD 0.064% plus calcipotriene 0.005% (Cal/BD) foam, Cal/BD cream, and HP 0.01% plus tazarotene 0.045% lotion. New treatments are on the horizon, with trials nearing completion for topical phosphodiesterase-4 inhibitors and tapinarof, and trials being planned for turmeric, rose bengal disodium, JAK-inhibitors, and pegcantratinib.
Summary: New therapeutic modalities can improve patient satisfaction and adherence, provide better control of disease, and improve quality of life. Thoughtful selection of the appropriate therapy from this growing arsenal will help improve patient care.